Semaglutide Plus Metformin Improves Weight and Fertility in Obese PCOS Patients

Combining semaglutide with metformin produced significant weight loss and improved fertility outcomes in 20 obese PCOS patients with prediabetes.

Bolek, Tomáš et al.·Clinical nutrition ESPEN·2026·
RPEP-148902026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Subcutaneous semaglutide combined with metformin produced significant weight loss and improved fertility outcomes in 20 consecutive PCOS patients with obesity and prediabetes.

Key Numbers

How They Did This

Pilot prospective study of 20 consecutive PCOS patients with obesity and prediabetes treated with semaglutide plus metformin, evaluating weight loss and fertility outcomes.

Why This Research Matters

PCOS affects 10% of women of reproductive age, and obesity worsens fertility outcomes. A treatment that addresses both weight and fertility simultaneously fills a critical gap.

The Bigger Picture

GLP-1 drugs may become standard preconception therapy for obese PCOS patients, addressing weight, insulin resistance, and fertility in one treatment approach.

What This Study Doesn't Tell Us

Small pilot study (n=20) without a control group. Prospective but not randomized or blinded. Short follow-up for fertility outcomes.

Questions This Raises

  • ?Should semaglutide be stopped before conception or can it continue through early pregnancy?
  • ?Does the fertility benefit persist after semaglutide discontinuation?

Trust & Context

Key Stat:
20 patients, dual benefit Semaglutide + metformin improved both weight and fertility in obese PCOS
Evidence Grade:
Small pilot prospective study without control — provides encouraging preliminary data requiring larger RCT confirmation.
Study Age:
Published in 2026; explores an emerging indication for GLP-1 drugs.
Original Title:
Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.
Published In:
Clinical nutrition ESPEN, 71, 102885 (2026)
Database ID:
RPEP-14890

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can semaglutide help PCOS patients get pregnant?

This pilot study suggests semaglutide combined with metformin can improve both weight loss and fertility in obese PCOS patients. Larger studies are needed, and semaglutide should be stopped before pregnancy.

Why does weight loss improve PCOS fertility?

Excess weight worsens insulin resistance and hormonal imbalances in PCOS. Even modest weight loss (5-10%) can restore ovulation and significantly improve chances of conception.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-14890·https://rethinkpeptides.com/research/RPEP-14890

APA

Bolek, Tomáš; Turňová, Petra; Janošova, Svetlana; Péč, Martin Jozef; Ságová, Ivana; Nagy, Norbert; Jurica, Jakub; Mokáň, Marián; Samoš, Matej. (2026). Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.. Clinical nutrition ESPEN, 71, 102885. https://doi.org/10.1016/j.clnesp.2025.102885

MLA

Bolek, Tomáš, et al. "Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.." Clinical nutrition ESPEN, 2026. https://doi.org/10.1016/j.clnesp.2025.102885

RethinkPeptides

RethinkPeptides Research Database. "Effect of semaglutide with metformin for weight loss and fer..." RPEP-14890. Retrieved from https://rethinkpeptides.com/research/bolek-2026-effect-of-semaglutide-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.